Why Medtronic stock got off to a big start this week

This is not uncommon for top medical device manufacturers. Medtronic (MDT 2.37%) To obtain regulatory approval for our products. Nonetheless, in the healthcare space, almost every regulatory victory is seen as a convincing victory for the company behind the product.

That’s what drove Medtronic’s stock price up more than 2% on Monday. That performance outperformed the overall stock market, at least considering the benchmark’s 1.4% gain. S&P 500 index.

Percept is now an approved product in the United States.

On Monday afternoon, Medtronic reported that its Percept RC deep brain stimulation (DBS) system has received approval from the U.S. Food and Drug Administration (FDA).

This electrically powered nerve stimulator is the latest in the specialty healthcare company’s Percept lineup. According to the manufacturer, the Percept product is the only detection-enabled DBS product currently available. Tailored treatment is available for people suffering from movement disorders such as Parkinson’s disease or epilepsy. Medtronic said that about 11 million people in the U.S. suffer from this disease.

DBS is a treatment that uses a surgically implanted medical device to directly deliver electrical signals to the brain area with movement disorders. Medtronic likened it to a heart pacemaker.

This isn’t the first Percept and I don’t think it will be the last.

The new Percept is likely to see robust acceptance in the target patient population, given its significant numbers. In a recent press release about the approval, Medtronic quoted Amaza Reitmeier, the company’s president and general manager of Brain Modulation, as saying, “Medtronic is committed to transforming treatments with the goal of improving the lives of more people. “We will continue to pursue this,” he said. DBS treatment.”